A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis

Inclusion Criteria:

• Subject must be receiving peritoneal dialysis or hemodialysis for at least 3 monthsprior to Screening

• Subject is currently being diagnosed and/or treated for secondary hyperparathyroidism

• For entry into the Dosing Period (for subjects that are naïve to Vitamin D Receptor [VDR] Activators or those who have completed a 2 to 12 week washout), the subject mustmeet the following laboratory criteria prior to enrollment:

• A corrected calcium value ≥ 8.2 and ≤ 10.4 mg/dL

• A phosphorus value ≤ 6.5 mg/dL

• An intact parathyroid hormone (iPTH) value > 300 pg/mL and less ≤ 2000 pg/mL

Exclusion Criteria:

• Subject is expected or scheduled to receive a living donor kidney transplant within 3months of Screening or is a kidney transplant patient requiring full immunosuppressanttherapy

• Subject is expected to stop peritoneal dialysis or hemodialysis within 4 months ofScreening (per investigator discretion)

• Subject has had a parathyroidectomy within 12 weeks prior to Screening

• Subject has had symptomatic or significant hypocalcemia requiring VDR Activatortherapy (i.e., calcitriol, paricalcitol, or doxercalciferol) within 2 months prior toScreening

• Subject is taking maintenance calcitonin, bisphosphonates, glucocorticoids in anequivalent dose of greater than 5 mg prednisone daily, or other drugs known to affectcalcium or bone metabolism within 4 to 8 weeks prior to Dosing

• Subject is receiving cinacalcet at the time of Screening